Clinical Trial News and Research

RSS

Combination of implanted DCs and EBRT effective in creating sarcoma tumor immune response

A team of 18 researchers at Moffitt Cancer Center in Tampa, Fla., have found that treating high-risk, soft tissue sarcoma patients with a combination of implanted dendritic cells (immune system cells) and fractionated external beam radiation (EBRT) provided more than 50 percent of their trial patients with tumor-specific immune responses lasting from 11 to 42 weeks.

2 Mar 2012

UCSD first to treat glioma with investigational viral vector

UC San Diego Moores Cancer Center researchers and surgeons are among the first in the nation to treat patients with recurrent brain cancer by directly injecting an investigational viral vector into their tumor. The treatment is being developed by a local San Diego Company, Tocagen Inc.

2 Mar 2012

Report highlights benefits of Nuvilex's cell encapsulation technology for diabetes

Nuvilex, Inc., an emerging biotechnology provider of cell and gene therapy solutions, today provided additional details based on the Goldman Small Cap Research report issued February 29, 2012, that highlighted the company's cell encapsulation technology and its benefits for treating chronic diseases such as diabetes.

2 Mar 2012

Parasitic worms could offer new treatment hope for MS patients

Parasitic worms could offer a new treatment hope for patients suffering from the autoimmune disease multiple sclerosis, scientists believe.

1 Mar 2012

TWRI team develops new drug against damaging effects of stroke

Scientists at the Toronto Western Research Institute (TWRI), Krembil Neuroscience Center, have developed a drug that protects the brain against the damaging effects of a stroke in a lab setting. This drug has been in development for a few years.

1 Mar 2012

Ruxolitinib boosts QOL and survival for patients with myelofibrosis

A drug that relieves the severe symptoms of a life-threatening bone marrow cancer called myelofibrosis also improves the survival of patients with the disease, according to a phase III clinical trial published in the March 1 edition of New England Journal of Medicine.

1 Mar 2012

Springer adds 6 new quarterly clinical review journals to medicine portfolio

Springer is adding six new quarterly clinical review journals to its existing medicine portfolio in March 2012. These new journals will expand the publisher's medical specialty coverage, focusing on dermatology, geriatrics/gerontology, nutrition, obesity, obstetrics/gynecology and respiratory care.

29 Feb 2012

Statins to carry revised warning labels: FDA

The U.S. FDA announced today that they would add additional safety warnings to the labels on statins, a class of drugs that lower cholesterol. Statins – with brand names Lipitor, Crestor and Zocor work by inhibiting the enzyme that plays a big part in the liver's production of cholesterol.

29 Feb 2012

Combination treatment for pancreatic cancer increases intratumoral gemcitabine levels

Oncologists who treat patients with pancreatic cancer may be one step closer to understanding why gemcitabine, the only currently available treatment, works in some cases but not in others, according to a paper in Cancer Discovery, a journal of the American Association for Cancer Research.

29 Feb 2012

Creabilis initiates CT327 Phase IIb trial in psoriasis vulgaris

Creabilis SA, a European biotechnology company specialising in the development of treatments for dermatology, inflammation and pain, today announced the start of the Phase IIb global clinical trial of its lead product CT327 in patients with psoriasis vulgaris. Recruitment is progressing well.

29 Feb 2012

EpiCept fourth quarter revenue decreases to $0.2 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2011, and provided an update on the Company's key business initiatives.

29 Feb 2012

FDA accepts Tau Therapeutics' mibefradil IND for treatment of cancer

Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that its investigational new drug application (IND 109196) for its novel drug mibefradil has been accepted by the Food and Drug Administration (FDA).

28 Feb 2012

GI Dynamics reports revenues of US$234,000 for year ended 31 December 2011

GI Dynamics, Inc., a company pioneering the development of effective, non-surgical approaches for treating type 2 diabetes and obesity, is pleased to provide its financial results for the year ended 31 December 2011.

28 Feb 2012

Baxter commences CD34+ stem cell phase III trial in CMI

Baxter International Inc. announced today that it has initiated a phase III pivotal clinical trial to evaluate the efficacy and safety of adult autologous (an individual's own) CD34+ stem cells to increase exercise capacity in patients with chronic myocardial ischemia (CMI).

From Baxter International Inc. 28 Feb 2012

Telephone-based counseling program does not improve osteoporosis medication adherence

Telephone motivational counseling sessions did not result in a statistically significant improvement in adherence to an osteoporosis medication regimen, according to a report published Online First by Archives of Internal Medicine, one of the JAMA/Archives journals.

28 Feb 2012

Vascular Magnetics to advance development of new drug delivery system for PAD

Vascular Magnetics, the first start-up company spun off by The Children's Hospital of Philadelphia, has raised $7 million to advance development of an innovative drug delivery system using magnetically targeted nanoparticles to treat peripheral artery disease.

28 Feb 2012

Enrollment complete in Ikaria iNO Pivotal Phase III trial for BPD

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that it has enrolled the last patient into its Pivotal Phase III trial investigating the use of inhaled nitric oxide (iNO) in premature infants with bronchopulmonary dysplasia (BPD).

27 Feb 2012

Opexa 2011 net loss increases to $5,968,448

Opexa Therapeutics, Inc., a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2011 and provided an overview of corporate developments during the last year.

27 Feb 2012

New method can predict whether Tylenol-poisoning patients need liver transplant

University of Utah mathematicians developed a set of calculus equations to make it easier for doctors to save Tylenol overdose patients by quickly estimating how much painkiller they took, when they consumed it and whether they will require a liver transplant to survive.

27 Feb 2012

The Lancet publishes Takeda's TAK-875 Phase 2 data on type 2 diabetes

Phase 2 clinical data of an investigational type 2 diabetes therapy, TAK-875 of Takeda Pharmaceutical Company Limited, were published online first in The Lancet.

27 Feb 2012